NCT05104866
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Chemotherapy, Therapeutic antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have been treated with 1 to 2 lines of prior standard of care chemotherapy in the metastatic setting
Exclusions: Patients with bone-only metastases; Patients with known, untreated, active brain metastases; Patients with leptomeningeal disease; Patients that have previously been treated with a chemotherapeutic agent targeting topoisomerase I or TROP2 (e.g. Enhertu/trastuzumab deruxtecan, Trodelvy/sacituzumab govitecan, datopotamab deruxtecan, irinotecan, etirinotecan pegol)
https://ClinicalTrials.gov/show/NCT05104866